[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bladder-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bladder-disease":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,82,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100495100","phase-3-the-role-of-preoperative-immunonutrition-on-morbidity-and-immune-response-after-cystectomy-incyst-trial-100495100",false,"NCT05726786","The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)","The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial)","INCyst","Inclusion Criteria:\n\n* Patient undergoing open cystectomy (for all reasons)\n* Age ≥18 years\n* Ability and willingness to provide informed consent documented by signature\n\nExclusion Criteria:\n\n* Contraindications to IN, e.g. known hypersensitivity or allergy to lactose, fish oil or soy lecithin\n* Severe diarrhoea requiring medical attention\n* Current treatment with any immunosuppressive drug\n* In standard practice, pregnant or lactating women are systematically rejected by the surgeon for this surgical procedure. Furthermore, during the pre-surgical anaesthesia consultation, the eligibility of each patient for anaesthesia will be assessed according to the usual criteria and recommendations of the anaesthesia service of the CHUV\n* Other clinically significant concomitant disease affecting immunity (e.g., severe renal failure, HIV, SLE, transplant recipient, ...)\n* Inability to follow the procedures of the study, e.g. due psychological disorders, dementia, etc.\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Use of IN independently of the study\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons\n* Emergency procedure (less than 7 days between screening and surgery)","ALL","18 Years",{"count":20,"type":21},232,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy.\n\nAs a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN.\n\nThis is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.",[27,28,29,30,31,32,33],"Bladder Cancer","Interstitial Cystitis","Painful Bladder Syndrome","Neurogenic Bladder","Hemorrhagic Cystitis","Endometriosis","Bladder Disease",[35,36,37,38],"Cystectomy","Immunonutrition","Complication","Malnutrition","RECRUITING","2025-12-02",{"date":42,"type":43},"2025-12-09","ACTUAL",{"date":45,"type":43},"2023-04-10",{"date":47,"type":21},"2026-10",{"name":49,"class":50},"Centre Hospitalier Universitaire Vaudois","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100542059","deceased-donor-bladder-or-combined-kidney-bladder-transplantation-a-phase-0-first-in-human-study-100542059","NCT06337942","Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study","Vascularized Composite Bladder Allograft Transplantation: a Phase 0 (First-in-human) Study for Deceased Donor Bladder or Combined Kidney-bladder Transplantation","Inclusion Criteria:\n\n* Age 18-70 years\n* Positive history of one of the following:\n\n  1. Terminal bladder pathology resulting in poor compliance, recurrent refractory infections, and\u002For and resultant upper tract (kidney and ureteral) pathology, with possible resultant kidney disease.\n  2. Localized, non-metastatic, bladder cancer requiring radical cystectomy. In this protocol, the only patients with a history of urothelial cell carcinoma that has already been treated, with an appropriate disease-free interval would be considered. Moreover, only candidates requiring a joint kidney and bladder transplantation or patients with a pre-existing transplant, on standard immunosuppression, will be considered.\n* Patients that are on immunosuppression for pre-existing solid organ transplantation will be included in this study.\n* Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regime.\n* Patient has been previously fully vaccinated and boosted against COVID-19, or is willing to undergo timely vaccination.\n\n  (a) Caretakers of the recipient will be strongly encouraged to be vaccinated.\n* Patients must demonstrate appropriate manual dexterity or sufficient assistance at home to perform clean intermittent catheterizations as needed. The patient (or assistant) must demonstrate proficiency in performing clean intermittent catheterization during pre-transplant workup.\n* No co-existing medical condition which, in the opinion of the study team, could affect the immunomodulatory protocol, surgical procedure, or functional results. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of genitourinary transplantation. Examples of such medical conditions would include burden of atherosclerotic disease that would preclude vascular anastomosis, and psychiatric disorders that would preclude reliable adherence to medications.\n* No active co-existing psychosocial problems (i.e., alcoholism, drug abuse).\n* Negative crossmatch with donor.\n\nExclusion Criteria:\n\n* Positive history of one of the following medical co-morbidities:\n\n  1. HIV (active or seropositive), active hepatitis B or C, viral encephalitis, untreated sepsis, active tuberculosis, viral encephalitis, toxoplasmosis, varicella zoster virus\n  2. Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like hemophilia, Von-Willebrand's disease, protein C and S deficiency, thrombocythemia, thalassemia, sickle cell disease.\n  3. Mixed connective tissue diseases and collagen disorders (can result in poor wound healing after surgery), including: mixed connective tissue disorder; severe deforming rheumatoid arthritis; infectious, post-infectious, or inflammatory (axonal or demyelinating) neuropathy; Ehlers-Danlos syndrome;\n  4. lipopolysaccharidosis or amyloidosis (effects nerve regeneration)\n  5. Impaired liver function as evaluated by liver function panel, including the presence of hyperbilirubinemia, elevated AST\u002FALT, and the presence of secondary coagulopathy, measured by prothrombin, international normalized ratio, and partial thromboplastin time.\n  6. Severe anemia (hemoglobin \\\u003C 7 g\u002FdL), leukopenia (WBC \\\u003C 3 x 109 cell\u002FL), or thrombocytopenia (platelets \\\u003C 20 x109 cells\u002FL).\n* Patient is either not vaccinated or is unwilling to undergo vaccination against COVID-19 prior to transplantation.\n* Oncology patient specific:\n\n  1. History of non-urothelial malignancy in past 5 years, with the exception of non-melanomatous skin cancer\n  2. History of malignancy involving metastases\n* Patients unable to receive adequate follow-up care and\u002For unable to receive immunosuppression due to geographic, financial or other reasons.\n* Patients with a smoking history who cannot demonstrate smoking cessation for a period of 6 months prior to listing and a desire to abstain from post-operative smoking will be excluded.\n* Records of poor medical compliance, documented psychological disorder(s), substance abuse or incomplete psychological clearance.\n* Particular attention will be paid to the candidate's compliance and their desire to undergo the offered procedure. While there is no \"score\" on any particular evaluation that would rule out a patient, certain factors can aid in the identification of patients who for example may not have the ability to comply with the medical directives necessary to care for a genitourinary transplant, or psychologically are not prepared for transplant, or who have unrealistic expectations about the transplant. The decision on eligibility is a team decision. All members of the team will discuss each candidate in a multidisciplinary meeting and reasons for concern over eligibility will be discussed at a Selection Committee Meeting. In circumstances where the candidate is considered to be less suitable, they could be given an opportunity to address these issues either through individual counseling or further education and then be reconsidered as a potential candidate. Every effort to prevent a request for allograft removal will be made.","70 Years",{"count":60,"type":21},5,[62],"NA","The goal of this clinical trial is to demonstrate the feasibility of bladder transplantation in patients with terminal bladder diseases who would benefit from a new bladder or a combined kidney and bladder transplant. The main questions it aims to answer are:\n\n* Is human bladder transplantation feasible and safe?\n* How will the new bladder function in terms of storage and emptying?\n\nParticipants will undergo a bladder-only or combined kidney and bladder transplantation. They will then be followed for two years to evaluate the efficacy, safety, and functionality of the bladder transplant.",[33,65,27,66],"Bladder, Neurogenic","Kidney Failure",[68,69,70,71],"terminal bladder","vascularized composite bladder allograft","bladder transplantation","combined kidney and bladder transplantation","2025-02-10",{"date":74,"type":43},"2025-02-12",{"date":76,"type":43},"2025-02-01",{"date":78,"type":21},"2028-01",{"name":80,"class":50},"University of California, Los Angeles",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":101,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100571359","evaluating-the-efficacy-and-patient-experience-of-catheter-free-intravesical-instillation-100571359","NCT06719232","Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation","Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation: a Prospective Observational Study","NOCATIN","Inclusion Criteria:\n\n* Male and female patients aged between 18 and 80 years.\n* Patients for whom the treating physician has determined that intravesical instillation is necessary due to one of the following conditions:\n* Interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS).\n* Recurrent urinary tract infections (UTIs).\n* Non-muscle invasive bladder cancer.\n* Post-radiation cystitis.\n* Post-chemotherapy cystitis.\n* Negative urine culture within the last two weeks.\n* Patients who provide verbal and written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Urinary tract infection within the past month or currently active infection.\n* Diagnosed bleeding disorders or recurrent macroscopic hematuria.\n* Post-void residual urine volume greater than 100 ml.\n* Mental condition that prevents reliable cooperation.","80 Years",{"count":92,"type":21},300,"OBSERVATIONAL","This study aims to evaluate a catheter-free method for delivering medications directly into the bladder, known as intravesical instillation, which is commonly used to treat conditions such as interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS), recurrent urinary tract infections, bladder cancer, and post-chemotherapy or post-radiation cystitis.\n\nThe study investigates whether this method, which eliminates the need for catheterization, reduces discomfort and complications while maintaining treatment effectiveness. By collecting data on patient experiences and outcomes, the study seeks to determine if this approach provides a safer and more comfortable alternative to traditional catheter-based treatments.",[28,96,97,27,33,98,99,100],"Recurrent Cystitis","Haemorrhagic Cystitis","Intravesical Instillation","Bladder Pain Syndrome","Recurrent Urinary Tract Infections",[102,103,104,105,106,107,108,109,110],"intravesical therapy","catheterization","recurrent urinary tract infection","IC\u002FBPS","Interstitial Cystitis\u002FBladder Pain syndrome","Post-chemotherapy Cystitis","Post-Irradiation Cystitis","Intravesical instillation","UroDapter","2024-12-07",{"date":113,"type":43},"2024-12-12",{"date":115,"type":43},"2024-10-01",{"date":117,"type":21},"2025-12",{"name":119,"class":120},"Jahn Ferenc South Pest Teaching Hospital","OTHER_GOV",2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":131,"conditions":132,"keywords":142,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":81},"100528944","study-on-the-occurrence-of-possible-relapses-and-on-the-quality-of-life-in-patients-who-underwent-turbk-100528944","NCT06167356","Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.","Observational Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent Endoscopic Resection Surgery for Bladder Cancer (TURBK).","Inclusion Criteria:\n\n* 18 years or older\n* Patients with non-muscle invasive bladder cancer\n* Indication to cancer removal through endoscopic resection surgery\n* Ability to read and sign the informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Inability to read and sign the informed consent",{"count":130,"type":21},20000,"A database has been created and will be used in which data will be collected in electronic format relating to adult patients who underwent one of the following endoscopic resection surgeries: TURBK, MAPPING, TURBK SECOND LOOK, BLADDER BIOPSIES.",[133,134,135,27,33,136,137,138,139,140,141],"Non Muscle Invasive Bladder Cancer","Non-Muscle Invasive Bladder Neoplasms","Non-Muscle Invasive Bladder Urothelial Carcinoma","Bladder Neoplasm","Bladder Urothelial Carcinoma","Bladder Cancer Stage I, With Cancer in Situ","Bladder Cancer Recurrent","Bladder Urothelial Carcinoma in Situ","Bladder Urothelial Dysplasia",[143,137,136,33,27,144],"Intravescical Therapies","Intravesical Instillations","2023-12-11",{"date":147,"type":43},"2023-12-12",{"date":149,"type":43},"2013-11-27",{"date":151,"type":21},"2063-11-27",{"name":153,"class":50},"IRCCS San Raffaele"]